McGowan, JV;
Chung, R;
Maulik, A;
Piotrowska, I;
Walker, JM;
Yellon, DM;
(2017)
Anthracycline Chemotherapy and Cardiotoxicity.
Cardiovascular Drugs and Therapy
, 31
(1)
pp. 63-75.
10.1007/s10557-016-6711-0.
Preview |
Text
art%3A10.1007%2Fs10557-016-6711-0.pdf - Published Version Download (631kB) | Preview |
Abstract
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon. Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient.
| Type: | Article |
|---|---|
| Title: | Anthracycline Chemotherapy and Cardiotoxicity. |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s10557-016-6711-0 |
| Publisher version: | http://dx.doi.org/10.1007/s10557-016-6711-0 |
| Language: | English |
| Additional information: | © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| Keywords: | Cancer anthracycline doxorubicin chemotherapy cardiotoxicity cardioprotection |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Pre-clinical and Fundamental Science |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1542954 |
Archive Staff Only
 |
View Item |
